

1 **Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine,**
2 **but strong initial responses to a third dose**

3

4 Francis Mwimanzi¹, Hope R. Lapointe², Peter K. Cheung^{1,2}, Yurou Sang¹, Fatima Yaseen¹, Gisele
5 Umviligihozo¹, Rebecca Kalikawe¹, Sneha Datwani¹, F. Harrison Omondi^{1,2}, Laura Burns³, Landon
6 Young³, Victor Leung^{4,5}, Olga Agafitei¹, Siobhan Ennis¹, Winnie Dong², Simran Basra¹, Li Yi Lim¹,
7 Kurtis Ng¹, Ralph Pantophlet¹, Chanson J. Brumme^{2,4}, Julio S.G. Montaner^{2,4}, Natalie Prystajecy^{5,6},
8 Christopher F. Lowe^{3,5}, Mari L. DeMarco^{3,5}, Daniel T. Holmes^{3,5}, Janet Simons^{3,5}, Masahiro Niikura¹,
9 Marc G. Romney^{3,5,*}, Zabrina L. Brumme^{1,2,*}, Mark A. Brockman^{1,2,*}

10

11 1. Faculty of Health Sciences, Simon Fraser University, Canada;

12 2. British Columbia Centre for Excellence in HIV/AIDS, Canada;

13 3. Division of Medical Microbiology and Virology, St. Paul's Hospital, Canada;

14 4. Department of Medicine, University of British Columbia, Canada;

15 5. Department of Pathology and Laboratory Medicine, University of British Columbia, Canada

16 6. British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada

17 *MAB, MGR and ZLB contributed equally

18

19 **Corresponding Author Contact Information:**

20 Mark A. Brockman, Ph.D.

21 Professor, Faculty of Health Sciences, Simon Fraser University

22 8888 University Drive, Burnaby, BC, Canada, V5A 1S6

23 Tel: 778 782-3341; Fax: 778-782-5927; email: mark_brockman@sfu.ca

24 **ABSTRACT**

25 **Background:** Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data
26 remain limited, particularly in older adults.

27 **Methods:** We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding
28 domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains
29 from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who
30 received COVID-19 mRNA vaccines.

31 **Results:** Following two vaccine doses, humoral immunity was weaker, less functional and less durable
32 in older adults, where a higher number of chronic health conditions was a key correlate of weaker
33 responses and poorer durability. Third doses boosted antibody binding and function to higher levels
34 than second-doses, and induced responses in older adults that were comparable in magnitude to those in
35 younger adults. Humoral responses against Omicron were universally weaker than against the ancestral
36 strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older
37 adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic
38 health conditions, but not age per se, was the strongest consistent correlate of weaker humoral
39 responses.

40 **Conclusion:** Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in
41 older adults.

42

43 **Key words:** COVID-19, mRNA vaccine, SARS-CoV-2, humoral immunity, older adults, binding
44 antibodies, ACE2 displacement, viral neutralization, Omicron

45

46 **INTRODUCTION**

47 Older adults are at increased risk of lethal COVID-19 following SARS-CoV-2 infection
48 (SARS-CoV-2) [1-3]. While two doses of a COVID-19 mRNA vaccine broadly protects against
49 hospitalization and death [4-6], weaker vaccine-induced immunity observed in the elderly and certain
50 other groups [7-12] has led to their prioritization to receive third doses [13-16]. Vaccine-induced
51 antibodies also decline over time, which can increase the risk of breakthrough infections [17-19],
52 particularly with the more transmissible and immune evasive Omicron variant (B.1.1.529) [20-22].

53 We and others have shown that older age is associated with weaker antibody responses to
54 COVID-19 mRNA vaccines, Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) [10-12]. We
55 previously characterized longitudinal humoral responses up to three months after the second vaccine
56 dose in a cohort of 151 adults 24 to 98 years of age that includes COVID-19 naïve and convalescent
57 individuals [12]. Here, we examine binding and neutralizing antibody responses up to six months
58 following the second vaccine dose, as well as one month following the third vaccine dose. We also
59 evaluate binding antibodies, ACE2 displacement, and virus neutralization against Omicron (BA.1) one
60 month following the second and third doses.

61

62 **METHODS**

63 **Study design.** We conducted a prospective longitudinal cohort study in British Columbia, Canada, to
64 examine SARS-CoV-2 specific humoral responses following vaccination with Comirnaty or Spikevax.
65 Our cohort of 151 individuals included 81 healthcare workers (HCW) and 56 older adults (including 18
66 residents of long-term care or assisted living facilities) who were COVID-19 naive at study entry, and
67 14 COVID-19 convalescent individuals with anti-SARS-CoV-2 N antibodies at study entry (including
68 8 HCW and 6 older adults) [12]. Serum and plasma were collected prior to vaccination; one month
69 after the first dose; one, three and six months after the second dose; and one month following the third
70 dose. Specimens were processed same-day and frozen until analysis.

71

72 **Ethics approval.** Written informed consent was obtained from all participants or their authorized
73 decision makers. This study was approved by the University of British Columbia/Providence Health
74 Care and Simon Fraser University Research Ethics Boards.

75

76 **Data sources.** Sociodemographic, health and vaccine information was collected by self-report and
77 confirmed through medical records where available. Chronic health conditions were defined as
78 hypertension, diabetes, asthma, obesity (body mass index ≥ 30), chronic diseases of lung, liver, kidney,
79 heart or blood, cancer, and immunosuppression due to chronic conditions or medication, to generate a
80 score ranging from 0-11 per participant [12].

81

82 **Binding antibody assays.** We measured total binding antibodies against SARS-CoV-2 nucleocapsid
83 (N) and spike (S) receptor binding domain (RBD) in serum using the Roche Elecsys Anti-SARS-CoV-
84 2 and Anti-SARS-CoV-2 S assays, respectively, on a Cobas e601 module analyzer (Roche

85 Diagnostics). Following SARS-CoV-2 infection, both assays should be positive, whereas post-
86 vaccination only the S assay should be positive, allowing identification of convalescent individuals.
87 Both tests are electro-chemiluminescence sandwich immunoassays, and report results in Arbitrary
88 Units (AU)/mL, calibrated against an external standard. For the S assay, the manufacturer indicates that
89 AU values can be considered equivalent to international binding antibody units (BAU) as defined by
90 the World Health Organization [23]. For the S assay, sera were tested undiluted, with samples above
91 the upper limit of quantification (ULOQ) re-tested at 1:100 dilution, allowing a measurement range of
92 0.4 - 25,000 U/mL. We also quantified plasma IgG binding antibodies against RBD using the V-plex
93 SARS-CoV-2 (IgG) Panel 22 ELISA kit (Meso Scale Diagnostics), which features the ancestral
94 (Wuhan) and Omicron RBD antigens, on a Meso QuickPlex SQ120 instrument. Plasma samples were
95 diluted 1:10000 as directed by the manufacturer, with results reported in Arbitrary Units (AU)/mL.

96

97 ***ACE2 competition assay.*** We assessed the ability of plasma antibodies to block the RBD-ACE2
98 receptor interaction by competition ELISA (Panel 22 V-plex SARS-CoV-2 [ACE2]; Meso Scale
99 Diagnostics) on a Meso QuickPlex SQ120 instrument. Plasma was diluted 1:20 as directed by the
100 manufacturer and results reported as % ACE2 displacement.

101

102 ***Live virus neutralization.*** Neutralizing activity in plasma was examined using a live SARS-CoV-2
103 infectivity assay in a Containment Level 3 facility. Assays were performed using isolate USA-
104 WA1/2020 (BEI Resources) and a local Omicron isolate (BA.1 strain; GISAID Accession #
105 EPI_ISL_9805779) on VeroE6-TMPRSS2 (JCRB-1819) target cells. Viral stock was adjusted to 50
106 TCID₅₀/200 µl in Dulbecco's Modified Eagle Medium in the presence of serial 2-fold dilutions of
107 plasma (from 1/20 to 1/2560), incubated at 4°C for 1 hour and then added to target cells in 96-well

108 plates in triplicate. Cultures were maintained at 37°C with 5% CO₂ and the appearance of viral
109 cytopathic effect (CPE) was recorded three days post-infection. Neutralizing activity is reported as the
110 highest reciprocal plasma dilution able to prevent CPE in all three replicate wells. Samples exhibiting
111 only partial or no neutralization at the lowest dilution of 1/20 were coded as having a reciprocal
112 dilution of "10", defined as below the limit of quantification (BLOQ) in this assay.

113

114 ***Statistical analysis.*** Comparisons of binary variables were performed using Fisher's exact test.

115 Comparisons of continuous variables were performed using the Mann-Whitney U-test (for unpaired

116 data) or Wilcoxon test (for paired data). Multiple linear regression was used to investigate the

117 relationship between sociodemographic, health and vaccine-related variables and humoral outcomes.

118 Variables included age (per year increment), sex at birth (female as reference group), ethnicity (non-

119 white as reference), number of chronic health conditions (per number increment), mRNA vaccine

120 received (Comirnaty as reference), interval between doses (per day increment), sampling date

121 following the most recent dose (per day increment), and convalescent status (COVID-19 naive as

122 reference). Binding antibody half-lives in serum were calculated by fitting exponential decay curves to

123 antibody concentrations at one, three and six months after the second dose. All tests were two-tailed,

124 with $p < 0.05$ considered statistically significant. Analyses were conducted using Microsoft Excel and

125 Prism v9.2.0 (GraphPad).

126

127 **RESULTS**

128 *Participant characteristics*

129 As described previously [12], the cohort is predominantly female (**Table 1**). HCW, older adults
130 and COVID-19 convalescent individuals at study entry were a median of 41, 79 and 48 years old,
131 respectively. Older adults were predominantly (77%) of white ethnicity (compared to 46% of HCW)
132 and had a higher burden of chronic health conditions (a median of 1, interquartile range [IQR] 0-2,
133 range 0-5, vs. a median of 1, IQR 0-0, range 0-3 in HCW). All participants received two COVID-19
134 mRNA vaccine doses between December 2020-July 2021, where the dose interval was up to 112 days
135 as per national guidelines to delay second doses due to initially limited vaccine supply. A total of 141
136 (93%) and 138 (91%) of participants received Comirnaty as their first and second dose, respectively. At
137 the time of writing, 114 participants had received a third dose between October-December 2021, on
138 average 7 months following their second dose. For participants whose third dose was Spikevax (53% of
139 the cohort), those aged ≥ 70 years received a full dose, whereas those < 70 years received a half-dose, as
140 per national guidelines. An additional six (7.4%) HCW and two (3.6%) older adults developed anti-N
141 antibodies during follow-up, reflecting breakthrough infections. Three of these infections, all in HCW,
142 occurred between December 2021-Jan 2022 and are likely Omicron. In longitudinal analyses that span
143 the entire study, participants with a post-vaccination SARS-CoV-2 infection are retained in their
144 original "COVID-19 naive at study entry" groups but identified in the Figures, while in analyses that
145 focus on third dose responses, they are grouped in a single "prior COVID-19" group.

146

147 *After two-dose vaccination, lower binding antibodies are associated with older age and burden of*
148 *chronic health conditions, but older adults mount strong responses after a third dose.*

149 We measured total anti-RBD binding antibody concentrations in serum before and after
150 immunization (**Figure 1A**). As reported previously [12], antibody concentrations in older adults were
151 significantly lower than those in HCW one month after the first dose (a median of 2.00 [IQR 1.75-2.25]
152 \log_{10} U/mL in HCW versus a median of 1.50 [IQR 1.05-1.99] in older adults), as well as one month
153 after the second dose (a median of 4.02 [IQR 3.88-4.25] in HCW versus a median of 3.74 [IQR 3.49-
154 3.91] in older adults) (Mann-Whitney; both $p < 0.0001$). Three months following the second dose,
155 antibody concentrations had declined by $\sim 0.4 \log_{10}$ on average, to a median of 3.63 [IQR 3.44-3.83] in
156 HCW versus a median 3.32 [IQR 3.04-3.56] in older adults) (Mann-Whitney $p < 0.0001$ for comparison
157 between groups). Six months following the second dose, antibody concentrations had declined by a
158 further $\sim 0.3 \log_{10}$ on average, to a median of 3.30 [IQR 3.09-3.47] in HCW versus a median 2.96 [IQR
159 2.68-3.20] in older adults ($p < 0.0001$). This confirms that, following two-dose COVID-19 mRNA
160 vaccination, antibody concentrations remain consistently and significantly lower in older compared to
161 younger adults. By contrast, antibody concentrations in COVID-19 convalescent individuals remained
162 consistently higher than COVID-19 naive individuals at all time points after two doses. Six months
163 after the second dose for example, convalescent individuals maintained median responses of 3.50 (IQR
164 3.40-3.71) \log_{10} U/mL ($p = 0.027$ compared to HCW; $p < 0.0001$ compared to older adults).

165 Multivariable analyses of antibody concentrations after two doses, that adjusted for sex ,
166 ethnicity, number of chronic health conditions, first-dose vaccine brand, dosing interval and day of
167 specimen collection post-immunization confirmed that older age remained independently associated
168 with lower antibody concentrations at one and three months after the second dose (**Table S1**). One
169 month following the second dose for example, each decade of older age was associated with an ~ 0.06
170 \log_{10} lower antibody concentration ($p = 0.0067$). A higher number of chronic conditions was also
171 independently associated with lower antibody concentrations at both these time points. Six months

172 following the second dose, a higher number of chronic health conditions remained the strongest
173 independent correlate of lower responses, with each additional condition associated with an 0.14 log₁₀
174 lower antibody concentration (p=0.0001). A longer dose interval was also associated with higher
175 antibody concentrations at all time points after the second dose (all p<0.05), consistent with previous
176 reports [24-26]. COVID-19 convalescent status was also associated with maintaining 0.26 log₁₀ higher
177 antibody concentrations at three and six months following the second dose (both p<0.05), consistent
178 with superior durability of “hybrid” immunity induced by infection followed by vaccination [27-29].

179 In both HCW and older adults, the third dose boosted antibody concentrations at least ~0.3-0.4
180 log₁₀ higher than peak values observed after two doses (Wilcoxon paired test p<0.0001 for both
181 groups). Binding antibodies in HCW rose to a median of 4.31 (IQR 4.13 to upper limit of quantification
182 [ULOQ]) whereas those in older adults rose to a median of 4.33 (4.14 to ULOQ) (p=0.33), indicating
183 that older and younger adults mounted comparable initial binding antibody responses following a third
184 dose. In multivariable analyses of third-dose responses, a higher number of chronic health conditions
185 was the sole significant correlate of lower antibody concentrations (p=0.0078), while having received
186 Spikevax as the third dose was associated with higher antibody concentrations (p=0.0091) (**Table S2**).

187

188 *After two-dose vaccination, weaker virus neutralizing activity is associated with age and chronic*
189 *health conditions, but older adults mount strong responses after a third dose.*

190 We performed live SARS-CoV-2 neutralization assays to quantify the ability of plasma to block
191 virus infection of target cells (**Figure 1B**). Neutralizing activity is reported as the highest reciprocal
192 plasma dilution capable of preventing viral cytopathic effects in all wells of a triplicate assay, where a
193 reciprocal dilution of "10" indicates no or limited neutralization. As previously reported [12], one
194 vaccine dose largely failed to induce neutralizing activity in COVID-19 naïve individuals, though two

195 doses induced this activity in most participants, albeit at consistently lower levels in older compared to
196 younger adults. One month after the second dose for example, the median reciprocal dilution was 160
197 [IQR 80-160] in HCW versus 40 [IQR 20-80] in older adults ($p<0.0001$). Three months after the
198 second dose, neutralizing activity had declined by more than two-fold on average, to a median
199 reciprocal dilution of 40 (IQR 20-80) in HCW versus a median of 20 (IQR BLOQ-40) in older adults
200 ($p<0.0001$). Six months after the second dose, neutralizing activity had declined to below the limit of
201 quantification (BLOQ) in 58% of HCW and 83% of older adults (Mann-Whitney $p=0.0048$ for
202 comparison between groups). COVID-19 convalescent individuals by contrast maintained significantly
203 higher neutralizing activity compared to naive individuals at all time points following two-dose
204 vaccination. Multivariable analyses confirmed that older age remained significantly associated with
205 weaker neutralizing activity at one and three months after two-dose vaccination, while COVID-19
206 convalescent status was associated with superior neutralizing activity at all time points following two-
207 dose vaccination (all $p\leq 0.0002$) (**Table S1**).

208 A third vaccine dose boosted neutralizing activity in both HCW and older adults, achieving
209 responses that were two-fold and eight-fold higher than peak values after two doses, respectively
210 (Wilcoxon paired test $p\leq 0.006$ for both groups; **Figure 1B**). Specifically, the median reciprocal dilution
211 in HCW and older adults rose to 320 [IQR 160-320] and 320 [IQR 80-320], respectively ($p=0.6$),
212 indicating that older adults mounted comparable neutralizing responses to younger adults after three
213 doses. A multivariable analysis identified prior COVID-19 as the strongest independent predictor of
214 higher neutralizing activity after a third vaccine dose ($p=0.0044$; **Table S2**).

215

216 *After two-dose vaccination, binding antibody responses decline faster in those with a higher burden*
217 *of chronic conditions.*

218 We next assessed temporal reductions in antibody concentrations after two-dose vaccination
219 (**Figure 2A**). Assuming exponential decay and restricting the analysis to participants with a complete
220 longitudinal data series with no values above the ULOQ, we estimated antibody concentration half-
221 lives to be a median of 59 [IQR 52-75] days in HCW versus a median of 52 [IQR 45-65] days in older
222 adults ($p=0.016$; **Figure 2B**). This suggests that, in addition to mounting overall weaker responses to
223 two-dose vaccination compared to younger adults, antibody concentrations in older adults also decline
224 more rapidly. In multivariable analyses however, a higher number of chronic health conditions
225 emerged as the sole independent correlate of antibody decline, with each additional condition
226 associated with a 5-day shorter half-life ($p=0.017$; **Table 2**). Furthermore, COVID-19 convalescent
227 status was associated with a 14-day longer antibody half-life after adjustment for other factors
228 ($p=0.056$), consistent with improved durability of hybrid immunity [27-29].

229

230 *Humoral responses against Omicron following two and three vaccine doses*

231 Given the rapid rise of the Omicron variant, we compared peak antibody responses against this
232 strain in plasma collected at one month after the second and third vaccine doses. Here, we grouped all
233 participants with prior COVID-19, regardless of infection timing, in the convalescent category. Overall,
234 IgG binding antibodies against the Omicron RBD, measured using the Meso Scale Diagnostics V-Plex
235 assay, were on average 0.4 to 0.5 \log_{10} U/mL lower than those against the wild type (WT; ancestral
236 Wuhan strain) RBD antigen after two and three doses (all within-group comparisons $p \leq 0.0002$; **Figure**
237 **3A**). Nevertheless, the third dose universally boosted anti-Omicron IgG concentrations to an average of
238 0.5 \log_{10} higher than levels induced by two doses (all within-group comparisons $p < 0.05$). Consistent
239 with total binding antibody concentrations quantified using the Roche assay (**Figure 1A**), binding IgG
240 concentrations against the WT RBD were significantly higher in HCW compared to older adults after

241 two doses ($p < 0.0001$) but reached equivalence after three doses ($p = 0.4$). IgG concentrations capable of
242 binding Omicron followed a similar pattern, with HCW showing marginally higher anti-Omicron IgG
243 levels compared to older adults after two doses ($p = 0.09$), but equivalent levels after three doses
244 ($p = 0.49$). A multivariable analysis of Omicron-specific IgG concentrations after three doses identified a
245 higher number of chronic health conditions as the strongest correlate of poorer responses, with each
246 additional condition associated with a 0.12 \log_{10} reduction in Omicron binding IgG ($p = 0.0033$; **Table**
247 **3**). A longer interval between the first and second vaccine doses was marginally associated with a
248 lower third dose response ($p = 0.02$).

249 We also assessed the ability of plasma to block the interaction between WT and Omicron RBD
250 and the cellular ACE2 receptor, which represents a higher throughput approach to estimate potential
251 virus neutralizing activity (also referred to as a surrogate virus neutralization test [30]). This activity
252 was significantly weaker against Omicron compared to WT RBD after both two and three doses in all
253 groups (all within-group comparisons $p \leq 0.0002$; **Figure 3B**), though the discrepancy was most
254 pronounced for older adults after two doses (where median activity against WT was 90% compared to
255 only 23% against Omicron). The third dose universally boosted anti-Omicron activity (all within-group
256 comparisons $p < 0.05$), with, for example, median anti-Omicron activity in older adults rising from 23%
257 after two doses to 66% after three. Consistent with results for binding IgG antibodies, surrogate
258 neutralization of WT RBD was significantly higher in HCW compared to older adults after two doses
259 ($p < 0.0001$), but reached equivalence after three doses (in fact, activities in older adults were slightly
260 higher at this time point; $p = 0.08$). Surrogate neutralization of Omicron RBD followed a similar pattern,
261 with HCW exhibiting significantly higher activity compared to older adults after two doses ($p < 0.0001$),
262 but equivalent levels after three doses ($p = 0.2$). In multivariable analyses, a higher number of chronic
263 health conditions was the strongest correlate of poorer surrogate neutralizing activity against Omicron

264 after three vaccine doses, with each additional condition associated with a ~6% reduction in this
265 activity ($p=0.0046$; **Table 3**). Male sex, a longer interval between the first and second doses, and the
266 number of days elapsed since the third dose also correlated with weaker responses after three doses (all
267 $p<0.05$).

268 Finally, we assessed plasma neutralizing activity against WT (ancestral USA-WA1/2020 strain)
269 and Omicron using a live virus assay in a subset of 20 HCW and 21 older adults who remained
270 COVID-19 negative throughout the study (**Figure 4**). Neutralizing activity against Omicron was
271 significantly weaker compared to WT following two and three doses in both groups (all $p<0.0001$). The
272 third dose nevertheless boosted anti-Omicron activity in both groups, where the increase in older adults
273 was particularly pronounced (from a median of BLOQ after the second dose to a median reciprocal
274 dilution of 40 after the third; $p<0.0001$). Consistent with binding IgG and surrogate neutralization
275 results, anti-Omicron neutralizing activity was significantly lower in older adults compared to HCW
276 after two vaccine doses ($p=0.0003$) but reached equivalence after the third dose ($p=0.79$).

277

278 **DISCUSSION**

279 At every time point following two doses of COVID-19 mRNA vaccine, antibody binding and
280 neutralizing activity were significantly weaker in older compared to younger adults. Antibody
281 concentrations were also less durable in older adults, though responses declined substantially in all
282 groups over time (*e.g.* by six months after the second dose, neutralizing activities had declined to
283 BLOQ in almost 60% of HCW and >80% of older adults). In multivariable analyses adjusting for
284 sociodemographic, health and vaccine-related variables, a higher number of chronic health conditions
285 remained consistently and independently associated with weaker and less durable binding antibody
286 responses, while a longer interval between first and second doses was consistently associated with
287 higher binding antibody responses after the second dose, as previously reported [24-26]. These findings
288 support public health decisions to provide third doses on or before the six-month mark, with older
289 adults receiving priority.

290 Third doses of COVID-19 vaccine increased antibody binding and neutralizing function to
291 levels that were significantly higher than those achieved by two doses, where the magnitude of
292 boosting in older adults was particularly prominent. Indeed, antibody binding, surrogate neutralization
293 and live virus neutralization activities in older adults were equivalent to those observed in younger
294 adults after three doses. Consistent with recent evidence [20, 21, 31-37], antibody responses against
295 Omicron were universally weaker than those against the ancestral strain after both two and three
296 vaccine doses; nevertheless, anti-Omicron responses in older adults reached equivalence to those
297 observed in younger adults after three doses. Notably, the number of chronic health conditions
298 persisted as an independent correlate of weaker anti-Omicron responses, even after three doses.

299 Similar to other reports [27-29], our findings indicate that individuals who have contracted
300 COVID-19 are likely to benefit from vaccination. Compared to naïve participants, convalescent

301 individuals displayed a slower rate of antibody decline, and multivariable analyses demonstrated that
302 binding and neutralization activity was higher in this group at six months after the second dose .

303 Our study has several limitations. As the precise immune correlates of protection for SARS-
304 CoV-2 transmission and disease severity remain incompletely characterized [38], the implications of
305 our results on individual-level protection from SARS-CoV-2 infection and COVID-19 remain
306 uncertain. We did not investigate T-cell responses, which may play critical roles in protection against
307 severe COVID-19, particularly in the context of variants [39-46]. Our study was not powered to
308 investigate potential differences in immune responses between the two mRNA vaccines [47, 48], nor
309 differences in full vs. half-doses of Spikevax when administered as third doses to individuals ≥ 70
310 versus < 70 years old, respectively, in Canada. Third dose responses were measured at a single time
311 point, so durability assessments are needed. Nevertheless, results provide additional insight into
312 COVID-19 mRNA vaccine immunogenicity in the elderly and in the context of an extended interval
313 between first and second doses (of up to 112 days).

314 In conclusion, while the observation of strong binding and neutralizing antibody responses to
315 third COVID-19 vaccine doses in older adults, including to Omicron, are encouraging, it will be
316 important to closely monitor the durability of these responses over time in this population.

317

318 **ACKNOWLEDGEMENTS**

319 We thank the leadership and staff of Providence Health Care, including long-term care and
320 assisted living residences, for their support of this study. We thank the phlebotomists and laboratory
321 staff at St. Paul's Hospital, the BC Centre for Excellence in HIV/AIDS and Simon Fraser University for
322 assistance. Above all, we thank the participants, without whom this study would not have been
323 possible.

324

325 **FUNDING**

326 This work was supported by the Public Health Agency of Canada through a COVID-19
327 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB, MAB).
328 Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 and
329 the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB), the Canada Foundation
330 for Innovation through Exceptional Opportunities Fund – COVID-19 awards (to MAB, MD, MN, RP,
331 ZLB) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health
332 (R01AI134229 to RP). MLD and ZLB hold Scholar Awards from the Michael Smith Foundation for
333 Health Research. LYL was supported by an SFU Undergraduate Research Award. GU and FHO hold
334 Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence
335 (SANTHE), a DELTAS Africa Initiative [grant # DEL-15-006]. The DELTAS Africa Initiative is an
336 independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating
337 Excellence in Science in Africa (AESAs) and supported by the New Partnership for Africa's
338 Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome
339 Trust [grant # 107752/Z/15/Z] and the UK government. The views expressed in this publication are

340 those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK
341 government.

342

343 **FIGURE LEGENDS**

344 **Figure 1. Longitudinal antibody binding and neutralization responses to spike RBD following**
345 **one, two and three COVID-19 vaccine doses. Panel A:** Binding antibody responses to the SARS-
346 CoV-2 spike RBD in serum, in HCW (blue circles) and older adults (orange circles) who were COVID-
347 19 naive at study entry, as well as COVID-19 convalescent individuals (black circles) at six timepoints:
348 prior to vaccination (pre-vax), one month following the first dose, one, three and six months following
349 the second dose, and one month following the third vaccine dose. Individuals with post-vaccination
350 infections are indicated by red dots at their first N seropositive time point. Participant Ns are provided
351 at the bottom of the plot. A thick horizontal red bar represents the median; thinner horizontal red bars
352 represent the IQR. P-values were computed using the Mann-Whitney U-test (for comparisons between
353 groups) or the Wilcoxon matched pairs test (for comparisons across time points within a group) and are
354 uncorrected for multiple comparisons. ULOQ/LLOQ: upper/lower limit of quantification. *Panel B:*
355 same as A, but for virus neutralization activity, defined as the lowest reciprocal plasma dilution at
356 which neutralization was observed in all wells of a triplicate assay. Plasma samples showing
357 neutralization in fewer than three wells at a 1/20 dilution were coded as having a reciprocal dilution of
358 10, corresponding to the LLOQ in this assay. The highest dilution tested was 1/2560, which
359 corresponds to the ULOQ. Note that only a subset of pre-vaccine plasma samples was assayed for this
360 activity.

361

362 **Figure 2: Decay rates of serum binding antibody responses to spike RBD following two COVID-**

363 **19 vaccine doses.** *Panel A:* Temporal declines in serum binding antibody responses to spike RBD
364 following two vaccine doses in HCW (blue) and older adults (orange) who were COVID-19 naive at
365 study entry, as well as COVID-19 convalescent participants (black circles). ULOQ: upper limit of
366 quantification. Only participants with a complete longitudinal data series with no values above the
367 ULOQ are shown. *Panel B:* Binding antibody half-lives following two COVID-19 vaccine doses,
368 calculated by fitting an exponential curve to each participant's data shown in panel A. Participant Ns
369 are indicated at the bottom of the plot. Red bars and whiskers represent the median and IQR. P-values
370 were computed using the Mann-Whitney U-test and are uncorrected for multiple comparisons.

371

372 **Figure 3: Anti-Omicron IgG binding and ACE2 displacement activities one month after the**

373 **second and third COVID-19 vaccine doses.** *Panel A:* Binding IgG responses in plasma to the wild-
374 type (WT, ancestral Wuhan strain) and Omicron (OM) S-RBD, measured using the Meso Scale
375 Diagnostics (MSD) V-Plex assay, in HCW (blue circles) and older adults (orange circles) who
376 remained COVID-19 naive throughout the study, as well as individuals with prior COVID-19
377 regardless of infection timing (COVID-19 convalescent; black circles) at one month after the second
378 and third COVID-19 vaccine doses. Participant Ns are shown at the bottom of the plot. A thick
379 horizontal red bar represents the median; thinner horizontal red bars represent the IQR. P-values were
380 computed using the Wilcoxon matched pairs test (for all within-group comparisons) or the Mann-
381 Whitney U-test (for between-group comparisons) and are uncorrected for multiple comparisons. *Panel*
382 *B:* same as A, but for ACE2 displacement activity, measured using the V-plex SARS-CoV-2 (ACE2)
383 assay, where results are reported in terms of % ACE2 displacement.

384

385 **Figure 4: Anti-Omicron neutralization activities one month after the second and third COVID-19**
386 **vaccine doses.** Neutralization activities, reported as the lowest reciprocal plasma dilution at which
387 neutralization was observed in all wells of a triplicate assay, against the wild-type (WT, ancestral
388 WA1/2020 strain) and Omicron (OM) virus isolates a subset of HCW (blue circles) and older adults
389 (orange circles) who remained COVID-19 naive throughout the study. Participant Ns are shown at the
390 bottom of the plot. A thick horizontal red bar represents the median; thinner horizontal red bars
391 represent the IQR. P-values were computed using the Wilcoxon matched pairs test (for within-group
392 comparisons) or the Mann-Whitney U-test (for between-group comparisons) and are uncorrected for
393 multiple comparisons.

394 **REFERENCES**

- 395 1. Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk Factors Associated With
396 Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care
397 Facilities in Ontario, Canada. *JAMA Netw Open* **2020**; 3:e2015957.
- 398 2. Chinnadurai R, Ogedengbe O, Agarwal P, et al. Older age and frailty are the chief predictors of
399 mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting- a
400 cohort study. *BMC Geriatr* **2020**; 20:409.
- 401 3. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated with the COVID-
402 19 pandemic according to underlying conditions and age: a population-based cohort study.
403 *Lancet* **2020**; 395:1715-25.
- 404 4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
405 Vaccine. *N Engl J Med* **2021**; 384:403-16.
- 406 5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
407 Vaccine. *N Engl J Med* **2020**; 383:2603-15.
- 408 6. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
409 Vaccination Setting. *N Engl J Med* **2021**; 384:1412-23.
- 410 7. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2
411 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. *Am J*
412 *Transplant* **2021**; 21:2719-26.

- 413 8. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of Seropositivity Following BNT162b2
414 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
415 JAMA Oncol **2021**; 7:1133-40.
- 416 9. Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of
417 the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective
418 observational study. Lancet Oncol **2021**; 22:765-78.
- 419 10. Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-
420 CoV-2 vaccine BNT162b2. Nature **2021**; 596:417-22.
- 421 11. Muller L, Andree M, Moskorz W, et al. Age-dependent Immune Response to the Biontech/Pfizer
422 BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis **2021**; 73:2065-72.
- 423 12. Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced magnitude and durability of humoral
424 immune responses to COVID-19 mRNA vaccines among older adults. J Infect Dis **2021**; Online
425 ahead of print. Accepted 9 Dec 2021. doi: 10.1093/infdis/jiab592.
- 426 13. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-
427 19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet **2021**;
428 398:2093-100.
- 429 14. Gilboa M, Mandelboim M, Indenbaum V, et al. Early Immunogenicity and safety of the third dose
430 of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience.
431 J Infect Dis **2021**; Online ahead of print. Accepted, 29 Nov 2021. doi: 10.1093/infdis/jiab584.

- 432 15. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against
433 Covid-19 in Israel. *N Engl J Med* **2021**; 385:1393-400.
- 434 16. Falsey AR, Frenck RW, Jr., Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine
435 Dose 3. *N Engl J Med* **2021**; 385:1627-9.
- 436 17. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough infections to
437 time-from-vaccine. *Nat Commun* **2021**; 12:6379.
- 438 18. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in
439 Israel. *N Engl J Med* **2021**; 385:e85.
- 440 19. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19
441 Vaccine over 6 Months. *N Engl J Med* **2021**; 385:e84.
- 442 20. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine
443 against Omicron Variant in South Africa. *N Engl J Med* **2022**; 386:494-6.
- 444 21. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer
445 BNT162b2 neutralization. *Nature* **2021**; Online ahead of print. Accepted, 23 Dec 2021. doi:
446 10.1038/s41586-021-04387-1.
- 447 22. Song JS, Lee J, Kim M, et al. Serial Intervals and Household Transmission of SARS-CoV-2
448 Omicron Variant, South Korea, 2021. *Emerg Infect Dis* **2022**; 28.
- 449 23. Bentley E, Mee ET, Routley S, et al. Collaborative Study for the Establishment of a WHO
450 International Standard for SARS-CoV-2 RNA. World Health Organization, Expert Committee on
451 Biological Standardization **2020**:WHO/BS/2020.402.

- 452 24. Amirthalingam G, Bernal JL, Andrews NJ, et al. Serological responses and vaccine effectiveness
453 for extended COVID-19 vaccine schedules in England. *Nat Commun* **2021**; 12:7217.
- 454 25. Parry H, Bruton R, Stephens C, et al. Differential immunogenicity of BNT162b2 or ChAdOx1
455 vaccines after extended-interval homologous dual vaccination in older people. *Immun Ageing*
456 **2021**; 18:34.
- 457 26. Payne RP, Longet S, Austin JA, et al. Immunogenicity of standard and extended dosing intervals of
458 BNT162b2 mRNA vaccine. *Cell* **2021**; 184:5699-714 e11.
- 459 27. Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor-binding domain
460 antibody evolution after mRNA vaccination. *Nature* **2021**; 600:517-22.
- 461 28. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing
462 antibodies elicited by SARS-CoV-2 infection. *Science* **2021**; 372:1413-8.
- 463 29. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against
464 SARS-CoV-2 one year after infection. *Nature* **2021**; 595:426-31.
- 465 30. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on
466 antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **2020**;
467 38:1073-8.
- 468 31. Doria-Rose NA, Shen X, Schmidt SD, et al. Booster of mRNA-1273 Strengthens SARS-CoV-2
469 Omicron Neutralization. *medRxiv* **2021**; Posted 20 Dec 2021. doi:
470 10.1101/2021.12.15.21267805. Preprint.

- 471 32. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-2
472 Omicron variant. medRxiv **2021**; Posted 13 Dec 2021. doi: 10.1101/2021.12.12.21267646.
473 Preprint.
- 474 33. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters
475 induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell **2022**; 185:457-66 e4.
- 476 34. Muik A, Lui BG, Wallisch AK, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2
477 mRNA vaccine-elicited human sera. Science **2022**; 375:678-80.
- 478 35. Debes AK, Xiao S, Egbert ER, et al. Comparison of total and neutralizing SARS-CoV-2 spike
479 antibodies against omicron and other variants in paired samples after two or three doses of
480 mRNA vaccine. medRxiv **2022**; Posted 31 Jan 2022. doi: 10.1101/2022.01.26.22269819.
481 Preprint.
- 482 36. Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other
483 SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect
484 **2022**; 11:337-43.
- 485 37. Muecksch F, Wang Z, Cho A, et al. Increased Potency and Breadth of SARS-CoV-2 Neutralizing
486 Antibodies After a Third mRNA Vaccine Dose. bioRxiv **2022**; Posted 15 Jan 2022. doi:
487 10.1101/2022.02.14.480394. Preprint.:2022.02.14.480394.
- 488 38. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic
489 SARS-CoV-2 infection. Nat Med **2021**; 27:2032-40.

- 490 39. Redd AD, Nardin A, Kared H, et al. Minimal cross-over between mutations associated with
491 Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19
492 convalescent individuals. *bioRxiv* **2021**; Posted 9 Dec 2021. doi: 10.1101/2021.12.06.471446.
493 Preprint.
- 494 40. Peng Y, Felce SL, Dong D, et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell
495 response controls viral replication and is associated with less severe COVID-19 disease. *Nat*
496 *Immunol* **2022**; 23:50-61.
- 497 41. Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells expand in
498 abortive seronegative SARS-CoV-2. *Nature* **2022**; 601:110-7.
- 499 42. Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response
500 against COVID-19. *Cell Host Microbe* **2021**; 29:1076-92.
- 501 43. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8
502 months after infection. *Science* **2021**; 371:eabf4063.
- 503 44. Riou C, Keeton R, Moyo-Gwete T, et al. Escape from recognition of SARS-CoV-2 variant spike
504 epitopes but overall preservation of T cell immunity. *Sci Transl Med* **2022**; 14:eabj6824.
- 505 45. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize
506 Omicron. *Nature* **2022**; Online ahead of print. Accepted, 31 Jan 2022. doi: 10.1038/s41586-022-
507 04460-3.

- 508 46. Liu J, Chandrashekar A, Sellers D, et al. Vaccines Elicit Highly Conserved Cellular Immunity to
509 SARS-CoV-2 Omicron. *Nature*; Online ahead of print, 31 Jan 2022. doi: 10.1038/s41586-022-
510 04465-y.
- 511 47. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 Antibody
512 Response Following Vaccination With BNT162b2 and mRNA-1273. *JAMA* **2021**; 326:1533-5.
- 513 48. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines
514 in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During
515 Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare
516 Safety Network, March 1-August 1, 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:1163-6.
- 517

Table 1: Participant characteristics and sampling information

Variable category	Characteristic	Healthcare Workers (n=81)	Older Adults (n=56)	COVID-19 Convalescent at study entry (n=14)
Sociodemographic/health	Age in years, median [IQR] ^a	41 [35-51]	78 [73-83]	48 [36-87]
	Female sex, n (%)	61 (75%)	38 (68%)	10 (71%)
	White/Caucasian ethnicity, n (%)	37 (46%)	43 (77%)	7 (50%)
	Chronic health or immunosuppressive conditions, median [IQR]	0 [0-0]	1 [0-2]	0 [0-1]
Vaccine information	Comirnaty, First mRNA Vaccine, n (%)	80 (99%)	48 (86%)	13 (93%)
	Comirnaty, Second mRNA Vaccine, n (%)	79 (98%)	46 (82%)	13 (93%)
	Time between first and second doses in days, median [IQR]	97 [91-102]	76 [45-85]	112 [87-118]
	Comirnaty, Third mRNA Vaccine, n (%) ^b	32/61 (52%)	19/47 (40%)	3/6 (50%)
	Time between second and third dose in days, median [IQR]	210 [200-241]	169 [160-231]	189 [170-194]
Specimen collection	Specimens collected pre-vaccine, n (%)	80 (99%)	49 (88%)	13 (93%)
	Specimens collected one month after first dose, n (%)	79 (98%)	49 (88%)	13 (93%)
	Day of specimen collection one month after first dose, median [IQR] days	28 [27-30]	30 [28-32]	31 [28-32]
	Specimens collected one month after second dose, n (%)	81 (100%)	55 (98%)	14 (100%)
	Day of specimen collection one month after second dose, median [IQR] days	29 [29-32]	29 [29-31]	32 [30-36]
	Specimens collected three months after second dose, n (%)	79 (98%)	53 (95%)	13 (93%)
	Day of specimen collection three months after second dose, median [IQR] days	90 [90-91]	90 [89-92]	90 [87-91]
	Specimens collected six months after second dose, n (%)	78 (96%)	40 (71%)	10 (71%)
	Day of specimen collection six months after second dose, median [IQR] days	181 [179-182]	176 [167-182]	180 [179-181]
	Specimens collected one month after third dose, n (%)	61 (75%)	47 (84%)	6 (38%)
	Day of specimen collection one month after third dose, median [IQR] days	30 [29-31]	32 [29-33]	30 [29-30]
COVID-19 post-vax	Anti-N seroconversion during study follow-up	6 (7.4%)	2 (3.6%)	-

^a interquartile range^b denominators are the n of specimens collected one month after third dose

Table 2: Multivariable analysis of the relationship between sociodemographic, health and vaccine-related variables on serum antibody half-life following two-dose COVID-19 mRNA vaccination

Outcome measure	Variable	Estimate	95% CI	p-value
Ab half-life after two vaccine doses	Age (per year)	0.058	-0.17 to 0.29	0.61
	Male sex	5.31	-2.57 to 13.18	0.18
	White ethnicity	3.11	-4.67 to 10.88	0.43
	# chronic conditions (per add'l)	-4.62	-8.39 to -0.85	0.017
	Spikevax as first dose	3.37	-13.26 to 20.00	0.69
	Dose interval (per day)	0.00014	-0.16 to 0.16	0.99
	COVID-19 convalescent ^a	13.78	-0.37 to 27.93	0.056

^a participants with positive anti-N serology at study entry


Table 3: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on Omicron-specific humoral immunogenicity measures following three-dose COVID-19 mRNA vaccination

Humoral measure	Variable	1 mo after 3rd dose		
		Estimate	95% CI	p-value
anti-Omicron RBD IgG (log10) ^a	Age (per year)	0.0035	-0.0027 to 0.0097	0.26
	Male sex	-0.14	-0.34 to 0.054	0.15
	White ethnicity	-0.018	-0.21 to 0.17	0.85
	# chronic conditions (per add'l)	-0.12	-0.20 to -0.041	0.0033
	Spikevax as third dose (vs. Comirnaty)	0.15	-0.039 to 0.34	0.12
	Interval between 1st and 2nd dose (per day)	-0.0066	-0.012 to -0.0011	0.020
	Interval between 2nd and 3rd dose (per day)	0.00043	-0.0034 to 0.0042	0.83
	Days since 3rd vaccine dose	-0.0086	-0.038 to 0.021	0.56
	Prior COVID-19 ^b	0.1	-0.16 to 0.37	0.43
anti-Omicron ACE2 % displacement ^a	Age (per year)	0.29	-0.046 to 0.63	0.090
	Male sex	-12.38	-23.16 to -1.60	0.025
	White Ethnicity	-2.36	-12.74 to 8.01	0.65
	# chronic conditions (per add'l)	-6.41	-10.80 to -2.03	0.0046
	Spikevax as third dose (vs. Comirnaty)	1.69	-8.58 to 11.97	0.74
	Interval between 1st and 2nd dose (per day)	-0.41	-0.71 to -0.11	0.0079
	Interval between 2nd and 3rd dose (per day)	-0.038	-0.25 to 0.17	0.72
	Days since 3rd vaccine dose	-1.82	-3.43 to -0.21	0.027
	Prior COVID-19 ^b	12.28	-2.11 to 26.67	0.094


^a Measured using the Meso Scale Diagnostics (MSD) V-plex assay system



^b Includes all participants with positive anti-N serology at any time during the study (*i.e.* both pre- and post-vaccine COVID-19 cases)

a




b





a



b




Figure 4




Table S1: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on immunogenicity measures following two-dose COVID-19 mRNA vaccination

Humoral measure	Variable	1 mo after 2nd dose			3 mo after 2nd dose			6 mo after 2nd dose		
		Estimate	95% CI	p-value	Estimate	95% CI	p-value	Estimate	95% CI	p-value
anti-RBD	Age (per year)	-0.0061	-0.010 to -0.0017	0.0067	-0.0047	-0.0085 to -0.00077	0.019	-0.0029	-0.0076 to 0.0018	0.22
Abs	Male sex	0.012	-0.14 to 0.17	0.88	0.089	-0.052 to 0.23	0.21	0.062	-0.083 to 0.21	0.40
(log ₁₀) ^a	White ethnicity	0.098	-0.056 to 0.25	0.21	0.15	0.012 to 0.29	0.033	0.089	-0.055 to 0.23	0.22
	# chronic cond. (per add'l)	-0.096	-0.17 to -0.022	0.011	-0.11	-0.18 to -0.047	0.001	-0.14	-0.21 to -0.068	0.0001
	Spikevax as first dose	0.25	-0.038 to 0.54	0.088	0.32	0.054 to 0.59	0.019	0.26	-0.039 to 0.57	0.087
	Dose interval (per day)	0.0034	0.00011 to 0.0067	0.043	0.0054	0.0025 to 0.0083	0.0003	0.0049	0.00194 to 0.0079	0.0014
	Days since 2nd dose	0.0039	-0.026 to 0.033	0.80	0.015	-0.0098 to 0.040	0.24	0.00095	-0.0088 to 0.010	0.85
	COVID-19 convalescent ^c	0.16	-0.087 to 0.42	0.20	0.23	0.0081 to 0.46	0.042	0.26	0.00938 to 0.51	0.042
Viral	Age (per year)	-0.018	-0.033 to -0.0030	0.019	-0.020	-0.034 to -0.0052	0.008	-0.0022	-0.016 to 0.012	0.75
neut	Male sex	-0.33	-0.85 to 0.18	0.21	0.22	-0.30 to 0.75	0.40	0.14	-0.29 to 0.57	0.53
(log ₂) ^b	White ethnicity	-0.075	-0.59 to 0.43	0.77	0.27	-0.24 to 0.78	0.30	0.067	-0.36 to 0.49	0.76
	# chronic cond. (per add'l)	-0.10	-0.34 to 0.14	0.42	-0.16	-0.40 to 0.095	0.22	-0.0080	-0.21 to 0.20	0.94
	Spikevax as first dose	0.86	-0.098 to 1.82	0.078	0.71	-0.30 to 1.7	0.17	0.81	-0.088 to 1.71	0.077
	Dose interval (per day)	0.0066	-0.0044 to 0.018	0.24	-0.00046	-0.011 to 0.010	0.93	0.0074	-0.0015 to 0.016	0.10
	Days since 2nd dose	0.0040	-0.094 to 0.10	0.94	-0.066	-0.16 to 0.026	0.16	0.010	-0.019 to 0.039	0.48
	COVID-19 convalescent	1.64	0.81 to 2.47	0.0001	1.84	1.0 to 2.7	<0.0001	1.46	0.72 to 2.19	0.0002

measured using the Elecsys Anti-SARS-CoV-2 S assay

for viral neutralization, reciprocal plasma dilutions were log₂ transformed prior to multivariable analysis.

participants with positive anti-N serology at study entry

Table S2: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on humoral responses following three-dose COVID-19 mRNA vaccination

Humoral measure	Variable	1 mo after 3rd dose		
		Estimate	95% CI	p-value
anti-RBD Abs (log ₁₀) ^a	Age (per year)	0.0018	-0.0011 to 0.0048	0.22
	Male sex	0.0080	-0.086 to 0.10	0.87
	White ethnicity	0.0089	-0.082 to 0.10	0.85
	# chronic conditions (per add'l)	-0.053	-0.091 to -0.014	0.0078
	Spikevax as third dose (vs. Comirnaty)	0.12	0.030 to 0.21	0.0091
	Interval between 1st and 2nd dose (per day)	-0.00064	-0.0033 to 0.0020	0.63
	Interval between 2nd and 3rd dose (per day)	0.00037	-0.0014 to 0.0022	0.69
	Days since 3rd vaccine dose	0.0016	-0.013 to 0.016	0.82
	Prior COVID-19 ^c	0.070	-0.057 to 0.20	0.28
Viral neut. (log ₂) ^b	Age (per year)	0.022	0.0025 to 0.042	0.028
	Male sex	-0.075	-0.70 to 0.55	0.81
	White ethnicity	-0.28	-0.88 to 0.33	0.37
	# chronic conditions (per add'l)	-0.17	-0.43 to 0.081	0.18
	Spikevax as third dose (vs. Comirnaty)	0.70	0.11 to 1.29	0.021
	Interval between 1st and 2nd dose (per day)	0.012	-0.0056 to 0.029	0.18
	Interval between 2nd and 3rd dose (per day)	0.013	0.00097 to 0.025	0.035
	Days since 3rd vaccine dose	-0.028	-0.12 to 0.065	0.55
	Prior COVID-19 ^c	1.23	0.39 to 2.06	0.0044

^a Measured using the Elecsys Anti-SARS-CoV-2 S assay

^b Viral neutralization results were log₂-transformed prior to multivariable analysis

^c Includes all participants with positive anti-N serology at any time during the study (*i.e.* both pre- and post-vaccine COVID-19 cases)